Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9832)
All Articles published online
|
Publishing Process of This Article
|
May 15, 2017 (publication date) through Nov 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pathophysiology
ISSN
2150-5330
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol 2017; 8(2): 51-58 [PMID: 28573067 DOI: 10.4291/wjgp.v8.i2.51] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5330/full/v8/i2/51.htm |
| Number | Citing Articles |
| 1 |
Michael B. Zemel, Orville Kolterman, Mary Rinella, Raj Vuppalanchi, Omar Flores, A. Sidney Barritt, Mohammad Siddiqui, Naga Chalasani. Randomized Controlled Trial of a Leucine‐Metformin‐Sildenafil Combination (NS‐0200) on Weight and Metabolic Parameters. Obesity 2019; 27(1): 59 doi: 10.1002/oby.22346
|
| 2 |
Ekram W. Abd El-Wahab, Rehab A. Zein El-Abedin, Walid M. Ahmed, Hanan Z. Shatat. Validation of a Non-Laboratory Based Screening Tool for Predicting Non-Alcoholic Fatty Liver Disease in an Egyptian Setting. The American Journal of the Medical Sciences 2020; 360(6): 662 doi: 10.1016/j.amjms.2020.06.020
|
| 3 |
Stephen A. Harrison, Salvatore Calanna, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun Sanyal, Anne-Sophie Sejling, Philip N. Newsome. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. Contemporary Clinical Trials 2020; 97: 106174 doi: 10.1016/j.cct.2020.106174
|
| 4 |
Shravan Dave, Abbey Barnard, Michel Mendler. CON: Noninvasive Imaging Is the Preferred Strategy for Cardiovascular Risk Stratification in This Patient. Clinical Liver Disease 2021; 17(1): 37 doi: 10.1002/cld.966
|
| 5 |
Emma Henriksson, Birgitte Andersen. FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Frontiers in Endocrinology 2020; 11 doi: 10.3389/fendo.2020.601349
|
| 6 |
Paul F. Lebeau, Jae Hyun Byun, Khrystyna Platko, Melissa E. MacDonald, Samantha V. Poon, Mahi Faiyaz, Nabil G. Seidah, Richard C. Austin. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice. Journal of Biological Chemistry 2019; 294(23): 9037 doi: 10.1074/jbc.RA119.008094
|
| 7 |
Samantha Thifani Alrutz Barcelos, Amanda Souza Silva-Sperb, Helena Abadie Moraes, Larisse Longo, Bruna Concheski de Moura, Matheus Truccolo Michalczuk, Carolina Uribe-Cruz, Carlos Thadeu Schmidt Cerski, Themis Reverbel da Silveira, Valesca Dall'Alba, Mário Reis Álvares-da-Silva. Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. Annals of Hepatology 2023; 28(1): 100769 doi: 10.1016/j.aohep.2022.100769
|
| 8 |
Harini Gurram, Jennifer Jo, Lisa B. VanWagner. Cardio-Hepatology. 2023; : 327 doi: 10.1016/B978-0-12-817394-7.00002-4
|
| 9 |
Ivica Grgurevic, Kristian Podrug, Ivana Mikolasevic, Michal Kukla, Anita Madir, Emmanuel A. Tsochatzis. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Canadian Journal of Gastroenterology and Hepatology 2020; 2020: 1 doi: 10.1155/2020/9181368
|
| 10 |
Nazanin Abbaspour, Traci Roberts, Shirin Hooshmand, Mark Kern, Mee Young Hong. Mixed Nut Consumption May Improve Cardiovascular Disease Risk Factors in Overweight and Obese Adults. Nutrients 2019; 11(7): 1488 doi: 10.3390/nu11071488
|
| 11 |
Anne Sophie Schou, Jonas Ellegaard Nielsen, Anders Askeland, Malene Møller Jørgensen. . Advances in Clinical Chemistry 2020; 99: 1 doi: 10.1016/bs.acc.2020.02.011
|
| 12 |
Luigi Castaldo, Federica Laguzzi, Rona J. Strawbridge, Damiano Baldassarre, Fabrizio Veglia, Lorenzo Vigo, Elena Tremoli, Ulf de Faire, Per Eriksson, Andries J. Smit, Jiri Aubrecht, Karin Leander, Matteo Pirro, Philippe Giral, Alberto Ritieni, Giovanni Di Minno, Anders Mälarstig, Bruna Gigante. Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study. Genes 2020; 11(11): 1243 doi: 10.3390/genes11111243
|
| 13 |
Mandeep K. Arora, Sudhanshu Pandey, Ritu Tomar, Jagannath Sahoo, Dinesh Kumar, Ashok Jangra. Therapeutic potential of policosanol in the concurrent management of dyslipidemia and non-alcoholic fatty liver disease. Future Journal of Pharmaceutical Sciences 2022; 8(1) doi: 10.1186/s43094-022-00399-4
|
| 14 |
Julie Rask Larsen, Lorena Dima, Christoph U. Correll, Peter Manu. The pharmacological management of metabolic syndrome. Expert Review of Clinical Pharmacology 2018; 11(4): 397 doi: 10.1080/17512433.2018.1429910
|
| 15 |
Isabelle E. Logan, Natalia Shulzhenko, Thomas J. Sharpton, Gerd Bobe, Kitty Liu, Stephanie Nuss, Megan L. Jones, Cristobal L. Miranda, Stephany Vasquez‐Perez, Jamie M. Pennington, Scott W. Leonard, Jaewoo Choi, Wenbin Wu, Manoj Gurung, Joyce P. Kim, Malcolm B. Lowry, Andrey Morgun, Claudia S. Maier, Jan F. Stevens, Adrian F. Gombart. Xanthohumol Requires the Intestinal Microbiota to Improve Glucose Metabolism in Diet‐Induced Obese Mice. Molecular Nutrition & Food Research 2021; 65(21) doi: 10.1002/mnfr.202100389
|
| 16 |
Maryam Kabootari, Mohammad Reza Raee, Samaneh Akbarpour, Samaneh Asgari, Fereidoun Azizi, Farzad Hadaegh. Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study. BMJ Open 2018; 8(11): e023735 doi: 10.1136/bmjopen-2018-023735
|
| 17 |
Yujun Liu, Yuan Gao, Fenglian Ma, Mengying Sun, Guangqing Mu, Yanfeng Tuo. The ameliorative effect of Lactobacillus plantarum Y44 oral administration on inflammation and lipid metabolism in obese mice fed with a high fat diet. Food & Function 2020; 11(6): 5024 doi: 10.1039/D0FO00439A
|
| 18 |
Parham Mardi, Reza Kargar, Ramina Fazeli, Mostafa Qorbani. Allium sativum: A potential natural compound for NAFLD prevention and treatment. Frontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1059106
|
| 19 |
R. A Eganyan. The role of non-alcoholic fatty liver disease in the development of cardiovascular diseases. CardioSomatics 2018; 9(1): 47 doi: 10.26442/CS45957
|
| 20 |
D Yu Serdyukov, A V Gordienko, I I Zhirkov, A S Fedorova, D A Sokolov, V T Dyidyishko, S V Apalko, S G Scherbak. Metabolic status, ultrasound changes of liver and vascular artery wall in men with abdominal obesity. Bulletin of the Russian Military Medical Academy 2020; 22(1): 31 doi: 10.17816/brmma25963
|
| 21 |
Ovidio De Filippo, Gianluca Di Pietro, Marco Nebiolo, Davide Giuseppe Ribaldone, Marco Gatti, Francesco Bruno, Guglielmo Gallone, Angelo Armandi, Lucia Ilaria Birtolo, Veronica Zullino, Gianluca Mennini, Stefano Ginanni Corradini, Massimo Mancone, Elisabetta Bugianesi, Mario Iannaccone, Gaetano Maria De Ferrari, Fabrizio D'Ascenzo. Increased prevalence of high‐risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: A meta‐analysis. European Journal of Clinical Investigation 2024; 54(9) doi: 10.1111/eci.14188
|
| 22 |
Amr Shaaban Hanafy, Waseem M. Seleem, Ferial El-kalla, Mohammad AbdAlkhalik Basha, Sherief Abd-Elsalam. Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019; 13(3): 2272 doi: 10.1016/j.dsx.2019.05.032
|
| 23 |
Neelakandan Ramya, Golepu Karthikeya, Sethu Prabhu Shankar. Association of Nonalcoholic Fatty Liver Disease with Coronary Artery Disease in Type 2 Diabetes Mellitus. Acta Medica International 2022; 9(1): 31 doi: 10.4103/amit.amit_25_22
|
| 24 |
Mai Salah Nour, Zeinab Abd El-Hay Sakara, Nawal Awad Hasanin, Shereen Mohamed Hamed. Histological and immunohistochemical study of the effect of liraglutide in experimental model of non-alcoholic fatty liver disease. Egyptian Journal of Basic and Applied Sciences 2023; 10(1): 342 doi: 10.1080/2314808X.2023.2204258
|
| 25 |
Rong Yang, Jian-Gao Fan. Non-alcoholic fatty liver disease and risk of cardiovascular diseases: clinical association, pathophysiological mechanisms, and management. Cardiology Plus 2023; 8(4): 217 doi: 10.1097/CP9.0000000000000067
|
| 26 |
Lingling Ding, Yvonne Oligschlaeger, Ronit Shiri-Sverdlov, Tom Houben. Prevention and Treatment of Atherosclerosis. Handbook of Experimental Pharmacology 2020; 270: 233 doi: 10.1007/164_2020_352
|
| 27 |
Faisal M Sanai, Faisal Abaalkhail, Fuad Hasan, Muhammad Hamed Farooqi, Nawal Al Nahdi, Zobair M Younossi. Management of nonalcoholic fatty liver disease in the Middle East. World Journal of Gastroenterology 2020; 26(25): 3528-3541 doi: 10.3748/wjg.v26.i25.3528
|
| 28 |
Stephen A Harrison, Vlad Ratziu, Jérôme Boursier, Sven Francque, Pierre Bedossa, Zouher Majd, Geneviève Cordonnier, Fouad Ben Sudrik, Raphael Darteil, Roman Liebe, Jérémy Magnanensi, Yacine Hajji, John Brozek, Alice Roudot, Bart Staels, Dean W Hum, Sophie Jeannin Megnien, Suneil Hosmane, Noémie Dam, Pierre Chaumat, Rémy Hanf, Quentin M Anstee, Arun J Sanyal. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology & Hepatology 2020; 5(11): 970 doi: 10.1016/S2468-1253(20)30252-1
|
| 29 |
Dongli Han, Haiying Zhang, Shousheng Liu, Likun Zhuang, Zhenzhen Zhao, Hongguang Ding, Yongning Xin. Association between the LRP5 rs556442 gene polymorphism and the risks of NAFLD and CHD in a Chinese Han population. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02385-9
|
| 30 |
Pegah Golabi, Munkhzul Otgonsuren, Leyla de Avila, Mehmet Sayiner, Nila Rafiq, Zobair M. Younossi. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine 2018; 97(13): e0214 doi: 10.1097/MD.0000000000010214
|
| 31 |
A V Gordienko, I I Zhirkov, D Yu Serdyukov. Lipid status and vascular bloodstream of servicemen with initial liver fibrosis. Bulletin of the Russian Military Medical Academy 2018; 20(1): 98 doi: 10.17816/brmma12232
|
| 32 |
Marialena Mouzaki, Amy Shah, Ana Catalina Arce-Clachar, Jennifer Hardy, Kristin Bramlage, Stavra A. Xanthakos. Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?. Journal of Clinical Lipidology 2019; 13(3): 425 doi: 10.1016/j.jacl.2019.02.002
|
| 33 |
Guglielmo M Trovato. Non-alcoholic fatty liver disease and Atherosclerosis at a crossroad: The overlap of a theory of change and bioinformatics. World Journal of Gastrointestinal Pathophysiology 2020; 11(3): 57-63 doi: 10.4291/wjgp.v11.i3.57
|
| 34 |
Hamza El Hadi, Angelo Di Vincenzo, Roberto Vettor, Marco Rossato. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2019; 20(9): 2215 doi: 10.3390/ijms20092215
|
| 35 |
Sandip Mukherjee, Jake Haubner, Anutosh Chakraborty. Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases. Molecules 2020; 25(6): 1403 doi: 10.3390/molecules25061403
|
| 36 |
D. V. Garbuzenko, D. V. Belov. Non-alcoholic fatty liver disease as an independent factor of cardiometabolic risk of cardiovascular diseases. Experimental and Clinical Gastroenterology 2021; (10): 22 doi: 10.31146/1682-8658-ecg-194-10-22-34
|
| 37 |
I. S. Dzherieva, N. I. Volkova, I. Y. Davidenko, I. B. Reshetnikov, S. S. Brovkina, S. M. Avakova, Y. V. Tishchenko. Glucocorticoid therapy is a risk factor for cardiovascular diseases. Medical Herald of the South of Russia 2022; 13(3): 93 doi: 10.21886/2219-8075-2022-13-3-93-106
|
| 38 |
Joanne M. Donkers, Reinout L.P. Roscam Abbing, Stan F.J. van de Graaf. Developments in bile salt based therapies: A critical overview. Biochemical Pharmacology 2019; 161: 1 doi: 10.1016/j.bcp.2018.12.018
|
| 39 |
E.P. Smuglov, E.V. Maksimova, D.G. Pashkovsky. Features of the management of coronary heart disease in patients with metabolically associated fatty liver disease. THE NEW ARMENIAN MEDICAL JOURNAL 2023; (2, 17 (2023)): 28 doi: 10.56936/18290825-2023.17.2-28
|
| 40 |
Fatemeh Ali Yari, Parisa Shabani, Sara Karami, Negar Sarmadi, Hossein Poustchi, Ahmad Reza Bandegi. Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease. BMC Endocrine Disorders 2021; 21(1) doi: 10.1186/s12902-021-00820-8
|
| 41 |
Gashaw Hassen, Abhishek Singh, Gizeshwork Belete, Nidhi Jain, Ivonne De la Hoz, Genesis P Camacho-Leon, Nitsuh K Dargie, Keila G Carrera, Tadesse Alemu, Sharan Jhaveri, Nebiyou Solomon. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus 2022; doi: 10.7759/cureus.25495
|
| 42 |
Mark Tomás Mc Auley. Biochemistry and Cell Biology of Ageing: Part I Biomedical Science. Subcellular Biochemistry 2018; 90: 99 doi: 10.1007/978-981-13-2835-0_4
|
| 43 |
S. V. Okovity, K. L. Raikhelson, A. V. Volnukhin, D. A. Kudlai. Hepatoprotective properties of glycyrrhizic acid. Experimental and Clinical Gastroenterology 2020; (12): 96 doi: 10.31146/1682-8658-ecg-184-12-96-108
|
| 44 |
Alexandra Jichitu, Simona Bungau, Ana Maria Alexandra Stanescu, Cosmin Mihai Vesa, Mirela Marioara Toma, Cristiana Bustea, Stela Iurciuc, Marius Rus, Nicolae Bacalbasa, Camelia Cristina Diaconu. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics 2021; 11(4): 689 doi: 10.3390/diagnostics11040689
|
| 45 |
Prabhudas Nelaturi, Sangeetha P Kademani, Vithiavathi Siva Subramanian, Sambandam Ravikumar. Increased Risk of Hypertension in Alcohol Use Disorder of alcohol-related Liver disease-A Hospital Based Case Control Study. Alcoholism Treatment Quarterly 2023; 41(1): 76 doi: 10.1080/07347324.2022.2135472
|
| 46 |
Farid Imanzadeh, Beheshteh Olang, Ali Akbar Sayyari, Naghi Dara, Katayoun Khatami, Amirhossein Hosseini, Maryam Kazemi Aghdam, Mitra Khalili, Mahmoud Hajipour, Zahra Fazeli Farsan, Negar Imanzadeh, Ayeh Yaraghi, Tahere Hatami, Shiva Mohammadi. Prevalence and Related Factors for Non-alcoholic Fatty Liver Disease in Obese Students. Journal of Comprehensive Pediatrics 2023; 14(3) doi: 10.5812/compreped-135095
|
| 47 |
O. S. Khukhlina, O. B. Kuzminska, O. S. Voievidka, Z. Ia. Kotsiubiichuk, V. V. Kropyva. Clinical Features of the Course of Non-Alcoholic Steatohepatitis with Comorbid Coronary Heart Disease. Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 2019; 4(1): 149 doi: 10.26693/jmbs04.01.149
|
| 48 |
Vardhmaan Jain, Raktim K. Ghosh, Dhrubajyoti Bandyopadhyay, Meera Kondapaneni, Samhati Mondal, Adrija Hajra, Wilbert S. Aronow, Carl J. Lavie. Serum Bilirubin and Coronary Artery Disease: Intricate Relationship, Pathophysiology, and Recent Evidence. Current Problems in Cardiology 2021; 46(3): 100431 doi: 10.1016/j.cpcardiol.2019.06.003
|
| 49 |
A. V. Nelidova, M. A. Livzan, N. A. Nikolaev, T. S. Krolevets. Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy. Rational Pharmacotherapy in Cardiology 2022; 17(6): 880 doi: 10.20996/1819-6446-2021-12-14
|
| 50 |
Mohammad Said Ramadan, Vincenzo Russo, Gerardo Nigro, Emanuele Durante-Mangoni, Rosa Zampino. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. Journal of Clinical Medicine 2021; 10(8): 1569 doi: 10.3390/jcm10081569
|
| 51 |
Ashley Patton, Tyler Church, Caroline Wilson, Jean Thuma, Douglas J Goetz, Darlene E Berryman, Edward O List, Frank Schwartz, Kelly D McCall. Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD. Journal of Endocrinology 2018; 237(3): 337 doi: 10.1530/JOE-18-0078
|
| 52 |
Marco Moroldo, Peris Mumbi Munyaka, Jérôme Lecardonnel, Gaëtan Lemonnier, Eric Venturi, Claire Chevaleyre, Isabelle P. Oswald, Jordi Estellé, Claire Rogel-Gaillard. Integrative analysis of blood and gut microbiota data suggests a non-alcoholic fatty liver disease (NAFLD)-related disorder in French SLAdd minipigs. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-019-57127-x
|
| 53 |
Maria-Daniela Dănilă, Marie Piollet, Oana-Maria Aburel, Denis Angoulvant, Claudie Lefort, Stéphanie Chadet, Sebastien Roger, Mirela-Danina Muntean, Fabrice Ivanes. Modulation of P2Y11-related purinergic signaling in inflammation and cardio-metabolic diseases. European Journal of Pharmacology 2020; 876: 173060 doi: 10.1016/j.ejphar.2020.173060
|
| 54 |
Ludovico Abenavoli, Maja Milanović, Nataša Milić, Francesco Luzza, Angelo Maria Giuffrè. Olive oil antioxidants and non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2019; 13(8): 739 doi: 10.1080/17474124.2019.1634544
|
| 55 |
Abeer Attia, Nargis Albert Labib, Noha Essameldin Elsayed Abdelzaher, Sherief Musa, Mira Atef. Lifestyle determinants as predictor of severity of metabolic associated fatty liver disease (MAFLD). Egyptian Liver Journal 2023; 13(1) doi: 10.1186/s43066-023-00282-8
|
| 56 |
Igor V. Maev, Alexey A. Samsonov, Leonid B. Lazebnik, Elena V. Golovanova, Chavdar S. Pavlov, Elena I. Vovk, Vlad Ratziu, Kirill M. Starostin. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Advances in Therapy 2020; 37(11): 4627 doi: 10.1007/s12325-020-01493-w
|
| 57 |
Bo Zhu, Siu-Lung Chan, Jack Li, Kathryn Li, Hao Wu, Kui Cui, Hong Chen. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Frontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.742382
|
| 58 |
Anh Ho, Takako Kiener, Quynh-Nhu Nguyen, Quang A. Le. Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD). Journal of Clinical Lipidology 2024; 18(4): e501 doi: 10.1016/j.jacl.2024.03.003
|
| 59 |
Pierluigi Marzuillo, Anna Di Sessa, Grazia Cirillo, Giuseppina Rosaria Umano, Marcella Pedullà, Angela La Manna, Stefano Guarino, Emanuele Miraglia del Giudice. Transmembrane 6 superfamily member 2 167K allele improves renal function in children with obesity. Pediatric Research 2020; 88(2): 300 doi: 10.1038/s41390-020-0753-5
|
| 60 |
Frank T. Spradley, Jillian A. Smith, Barbara T. Alexander, Christopher D. Anderson. Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease. American Journal of Physiology-Endocrinology and Metabolism 2018; 315(5): E795 doi: 10.1152/ajpendo.00394.2017
|
| 61 |
Wen-Chung Huang, Ya-Ling Chen, Hui-Chia Liu, Shu-Ju Wu, Chian-Jiun Liou. Ginkgolide C reduced oleic acid-induced lipid accumulation in HepG2 cells. Saudi Pharmaceutical Journal 2018; 26(8): 1178 doi: 10.1016/j.jsps.2018.07.006
|
| 62 |
Toba Kazemi, Bita Bijari, Farshad Sharifi, Mitra Moodi, Farhad Saeedi, Saeede Khosravi Bizhaem, Fatemeh Hoseinzadeh-Chahkandak, Saeed Samarghandian, Tahereh Farkhondeh. Prevalence of Metabolic Syndrome and Its Associated Potential Factors
among the Elderly in the East of Iran. Current Diabetes Reviews 2023; 19(3) doi: 10.2174/1573399818666220606143934
|
| 63 |
Damilola D. Adingupu, Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan, Ann-Cathrine Jönsson-Rylander. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice. Cardiovascular Diabetology 2019; 18(1) doi: 10.1186/s12933-019-0820-6
|
| 64 |
Ugur Arslan, Mustafa Yenerçağ. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World Journal of Clinical Cases 2020; 8(20): 4688-4699 doi: 10.12998/wjcc.v8.i20.4688
|
| 65 |
Melanie Cree-Green. Editoral commentary: Understanding cardiovascular disease risk in women with polycystic ovary syndrome. Trends in Cardiovascular Medicine 2020; 30(7): 405 doi: 10.1016/j.tcm.2019.09.004
|
| 66 |
Ahmed S. Elsawaby, Rawia A. Al-Fiky, Azza E. Mohamed, Hossam El Din A. Mahmoud, Shereen A. Saleh, Haitham G. Mohammed, Iman F. Montasser, Mohammed H. Abdelbary. Electrocardiographic and echocardiographic changes in nonalcoholic fatty liver disease. The Egyptian Journal of Internal Medicine 2019; 31(2): 191 doi: 10.4103/ejim.ejim_95_18
|
| 67 |
Ju Hyun Kang, Sun Jae Park, Seogsong Jeong, Young Jun Park, Hye Jun Kim, Jihun Song, Jiwon Choi, Sangwoo Park, Jaewon Kim, Hyeokjong Lee, Jooyoung Chang, Joung Sik Son, Sang Min Park. Association between antibiotic use and cardiovascular diseases in metabolic dysfunction‐associated steatotic liver disease: A nationally representative retrospective cohort study. Hepatology Research 2024; doi: 10.1111/hepr.14115
|
| 68 |
Karthik Chandrasekharan, William Alazawi. Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?. Frontiers in Pharmacology 2020; 10 doi: 10.3389/fphar.2019.01413
|
| 69 |
Fan Yang, Ping Huang, Liandong Shi, Feng Liu, Aimei Tang, Shaohui Xu. <p>Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice</p>. Drug Design, Development and Therapy 2020; : 3865 doi: 10.2147/DDDT.S258857
|
| 70 |
Lidia Castagneto-Gissey, Stefan R. Bornstein, Geltrude Mingrone. Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review. Metabolism 2024; 151: 155721 doi: 10.1016/j.metabol.2023.155721
|
| 71 |
Gerardo Rodriguez-Araujo, Andrew J. Krentz. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019; : 275 doi: 10.1007/978-3-030-11748-1_11
|
| 72 |
Miori Tanaka, Akari Sato, Yoshimi Kishimoto, Hideaki Mabashi-Asazuma, Kazuo Kondo, Kaoruko Iida. Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. Nutrients 2020; 12(5): 1479 doi: 10.3390/nu12051479
|
| 73 |
Marília Marques Pereira Lira, José Eymard Moraes de Medeiros Filho, Vinícius José Baccin Martins, Gitana da Silva, Francisco Antônio de Oliveira Junior, Éder Jackson Bezerra de Almeida Filho, Alexandre Sérgio Silva, João Henrique da Costa-Silva, José Luiz de Brito Alves, Oscar Millet. Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. PLOS ONE 2020; 15(8): e0237360 doi: 10.1371/journal.pone.0237360
|
| 74 |
Xingming Li, Yuliang Cheng, Jiayi Li, Chang Liu, He Qian, Genyi Zhang. Torularhodin Alleviates Hepatic Dyslipidemia and Inflammations in High-Fat Diet-Induced Obese Mice via PPARα Signaling Pathway. Molecules 2022; 27(19): 6398 doi: 10.3390/molecules27196398
|
| 75 |
Federica Fogacci, Maciej Banach, Arrigo Francesco Giuseppe Cicero. Resveratrol effect on patients with non‐alcoholic fatty liver disease: A matter of dose and treatment length. Diabetes, Obesity and Metabolism 2018; 20(7): 1798 doi: 10.1111/dom.13324
|
| 76 |
José Antonio Orozco Morales, Aída Xochitl Medina Urrutia, Margarita Torres Tamayo, Esteban Jorge Galarza, Juan Reyes Barrera, Pilar Díes Suarez, Juan Gabriel Juárez Rojas, Patricia Medina‐Bravo. Effects of fatty liver on the size and composition of high‐density lipoprotein cholesterol subpopulations in adolescents with type 2 diabetes mellitus. Pediatric Diabetes 2020; 21(7): 1140 doi: 10.1111/pedi.13103
|
| 77 |
Optimization of Treatment of Patients with Ischemic Heart Disease Combined with Nonalcoholic Fatty Liver Disease. Family medicine 2019; (5-6): 96 doi: 10.30841/2307-5112.5-6.2019.194247
|
| 78 |
Jonathan Zhi Kai Toh, Xin-Hui Pan, Phoebe Wen Lin Tay, Cheng Han Ng, Jie Ning Yong, Jieling Xiao, Jin Hean Koh, En Ying Tan, Eunice Xiang Xuan Tan, Yock Young Dan, Poay Huan Loh, Roger Foo, Nicholas W.S. Chew, Arun J. Sanyal, Mark D. Muthiah, Mohammad Shadab Siddiqui. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2022; 20(11): 2462 doi: 10.1016/j.cgh.2021.09.021
|
| 79 |
Gerardo Rodriguez-Araujo. Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists. Cardiovascular Endocrinology & Metabolism 2020; 9(3): 96 doi: 10.1097/XCE.0000000000000197
|
| 80 |
Seon-Ok Lee, Yinzhu Xu, Hengmin Han, Seok-Tae Jeong, You-Kyung Lee, Jean Kyung Paik, Jin-Sol Cha, Hyo-Jeong Lee. Fermented Rhus Verniciflua Stokes Extract Alleviates Nonalcoholic Fatty Liver through the AMPK/SREBP1/PCSK9 Pathway in HFD-Induced Nonalcoholic Fatty Liver Animal Model. Applied Sciences 2020; 10(19): 6833 doi: 10.3390/app10196833
|
| 81 |
Anchalia Chandrakumaran, Mohammad Shadab Siddiqui. Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. Gastroenterology Clinics of North America 2020; 49(1): 165 doi: 10.1016/j.gtc.2019.09.005
|
| 82 |
Marco Raffaele, Giuseppe Carota, Giuseppe Sferrazzo, Maria Licari, Ignazio Barbagallo, Valeria Sorrenti, Salvatore S. Signorelli, Luca Vanella. Inhibition of Heme Oxygenase Antioxidant Activity Exacerbates Hepatic Steatosis and Fibrosis In Vitro. Antioxidants 2019; 8(8): 277 doi: 10.3390/antiox8080277
|
| 83 |
Bassam Mohamed Ali, Eman M. Elbaz, Asmaa K. Al‐Mokaddem, Soad Z. El‐Emam, Magdy M. Awny. Delphinidin or α‐amyrin attenuated liver steatosis and metabolic disarrangement in rats fed a high‐fat diet. BioFactors 2024; doi: 10.1002/biof.2133
|
| 84 |
Petar Avramovski, Maja Avramovska, Zorica Nikleski, Biljana Ilkovska, Kosta Sotiroski, Emilija Sikole. The predictive value of the hepatorenal index for detection of impaired glucose metabolism in patients with non-alcoholic fatty liver disease. Indian Journal of Gastroenterology 2020; 39(1): 50 doi: 10.1007/s12664-019-01009-7
|
| 85 |
Helda Tutunchi, Fatemeh Naeini, Mehrangiz Ebrahimi‐mameghani, Majid Mobasseri, Sina Naghshi, Alireza Ostadrahimi. The association of the steatosis severity, NAFLD fibrosis score and FIB‐4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross‐sectional study. International Journal of Clinical Practice 2021; 75(6) doi: 10.1111/ijcp.14131
|
| 86 |
Maryam Chegeni, Sairan Nili, Mehdi Darabi, Elham Gheysvandi, Razieh Zahedi, Elham Sharifian, Hamid Reza Shoraka, Mohammad Rostamkhani, Leili Abedi Gheshlaghi. Prevalence of non-alcoholic fatty liver and its related factors in Iran: Systematic review and meta-analysis. Journal of Education and Health Promotion 2023; 12(1) doi: 10.4103/jehp.jehp_1056_22
|
| 87 |
Aline Gottlieb, Anna-Sophia Leven, Jan-Peter Sowa, Katrin Borucki, Alexander Link, Elvan Yilmaz, Sitke Aygen, Ali Canbay, Mustafa Porsch-Özcürümez. Lipoprotein and Metabolic Profiles Indicate Similar Cardiovascular Risk of Liver Steatosis and NASH. Digestion 2021; 102(5): 671 doi: 10.1159/000510600
|
| 88 |
Fatemeh Naeini, Zahra Namkhah, Helda Tutunchi, Seyed Mahdi Rezayat, Siavash Mansouri, Mehdi Yaseri, Mohammad Javad Hosseinzadeh-Attar. Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial. European Journal of Gastroenterology & Hepatology 2022; 34(3): 345 doi: 10.1097/MEG.0000000000002323
|
| 89 |
Philip N. Newsome, Arun J. Sanyal, Kristiane A. Engebretsen, Iris Kliers, Laura Østergaard, Denise Vanni, Elisabetta Bugianesi, Mary E. Rinella, Michael Roden, Vlad Ratziu. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Alimentary Pharmacology & Therapeutics 2024; 60(11-12): 1525 doi: 10.1111/apt.18331
|
| 90 |
Sha Li, Hor Yue Tan, Ning Wang, Fan Cheung, Ming Hong, Yibin Feng, Sharad S. Singhal. The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases. Oxidative Medicine and Cellular Longevity 2018; 2018(1) doi: 10.1155/2018/8394818
|
| 91 |
Jamili D.B. Santos, Andréa A.S. Mendonça, Rafaela C. Sousa, Thaiany G.S. Silva, Solange M. Bigonha, Eliziária C. Santos, Reggiani V. Gonçalves, Rômulo D. Novaes. Food-drug interaction: Anabolic steroids aggravate hepatic lipotoxicity and nonalcoholic fatty liver disease induced by trans fatty acids. Food and Chemical Toxicology 2018; 116: 360 doi: 10.1016/j.fct.2018.04.056
|
| 92 |
Paul F. Lebeau, Jae Hyun Byun, Khrystyna Platko, Ali A. Al-Hashimi, Šárka Lhoták, Melissa E. MacDonald, Aurora Mejia-Benitez, Annik Prat, Suleiman A. Igdoura, Bernardo Trigatti, Kenneth N. Maclean, Nabil G. Seidah, Richard C. Austin. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Reports 2019; 1(6): 418 doi: 10.1016/j.jhepr.2019.10.009
|
| 93 |
Shusei Yamamoto, Ikumi Sato, Natsuki Fukuhama, Natsumi Akiyama, Miku Sakai, Shota Kumazaki, Shang Ran, Satoshi Hirohata, Kazuya Kitamori, Yukio Yamori, Shogo Watanabe. Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5/Dmcr rat model. Experimental and Molecular Pathology 2020; 114: 104437 doi: 10.1016/j.yexmp.2020.104437
|